So, you know how everyone in biotech is trying to build a better blood test to catch cancer early? Well, Caris Life Sciences (CAI) just dropped some fresh data suggesting its approach might be working. The stock popped in premarket trading Wednesday after the company announced the finalized results from its Achieve 1 study.
The big takeaway? The company's multi-cancer early detection test, called Caris Detect, looks pretty good when you stack it up against traditional methods. The study, which enrolled over 3,000 subjects, is designed to show how well the test can spot various cancers at early stages from just a blood sample. For a test aimed at a high-risk population, that's the kind of data you need to start building a case for its use.
Caris is using something called Whole Genome Sequencing in its test, which basically means it's looking at a person's entire genetic blueprint for molecular changes that drive cancer. The idea is that by casting such a wide net, you can catch more signals. The company says this approach showed "superior sensitivity and specificity," and it plans to add even more layers of analysis, like Whole Transcriptome Sequencing, to make the test even sharper.
This isn't the first peek at this data; the company shared an interim readout back in February. But final results tend to carry more weight. Caris also highlighted the sheer scale of its data operation, noting it has processed over a million cases, generating more than 50 billion molecular markers. That's the kind of massive dataset you'd want if you're planning to use artificial intelligence to help find the needle-in-a-haystack signals of early cancer.
The Financial Engine Behind the Science
Now, all this promising science is happening alongside some pretty explosive financial results. Caris recently reported its fourth-quarter earnings, and the numbers were strong.
The company posted earnings of 28 cents per share, which was a surprise beat compared to the consensus estimate for a loss of 3 cents. But the real story was on the top line. Sales skyrocketed 125% year-over-year to $292.89 million, blowing past the $208.63 million analysts were expecting.
What's driving that growth? Almost entirely the company's core business: molecular profiling services. Revenue from that segment jumped 199% to $282.1 million. Management attributed the surge to an increase in total clinical case volume and improvements in the average selling price across its therapy selection solutions. In plain English, they're doing more tests and getting paid more for them.
Specifically, the company completed about 52,700 clinical therapy selection cases in the quarter, up roughly 20% from the prior year. That breaks down to about 44,150 cases of its MI Profile and approximately 8,550 cases of its Caris Assure product.
Looking ahead, Caris provided guidance for fiscal 2026, expecting sales between $1 billion and $1.02 billion. It's worth noting that this forecast is slightly below the current consensus estimate of about $1.198 billion.
What the Charts Are Saying
Okay, so the news is good and the recent earnings were great. But what about the stock's recent performance? The technical picture tells a more nuanced story.
As of this latest move, the stock was still trading about 1.84% below its 20-day simple moving average and a more significant 12.09% below its 100-day average. That generally indicates a bearish short-term trend. Zooming out, shares are down about 36% over the past 12 months and are trading closer to their 52-week lows than their highs.
Some of the momentum indicators, however, are hinting at a potential shift. The Relative Strength Index (RSI) is sitting at 41.87, which is considered neutral territory—neither overbought nor oversold. More interestingly, the Moving Average Convergence Divergence (MACD) indicator is at -0.7990, with its signal line at -0.8267. Because the MACD is above the signal line, it's technically giving a bullish signal.
So, you have a neutral RSI and a bullish MACD. Traders might look at that as a sign of mixed momentum, suggesting that while the stock isn't oversold and ripe for a snap-back rally, there might be some underlying strength building for a move higher.
For those watching the levels, key resistance is seen around $20.00, while key support sits near $16.50.
Putting it all together, Caris Life Sciences shares were up 6.49% at $19.04 in premarket trading Wednesday. The market is clearly reacting positively to the final Achieve 1 data, which bolsters the narrative around its flagship early detection test. Now investors will be watching to see if this scientific validation can help the stock break out of its longer-term downtrend and challenge that $20 resistance level.
